HIGH SERUM LEVELS OF TNF-ALPHA AFTER ITS ADMINISTRATION FOR ISOLATION PERFUSION OF THE LIMB

被引:31
作者
GERAIN, J
LIENARD, D
EWALENKO, P
LEJEUNE, FJ
机构
[1] UNIV LIBRE BRUXELLES, CTR TUMEURS, INST JULES BORDET, SERV MED INTERNE, B-1000 BRUSSELS, BELGIUM
[2] UNIV LIBRE BRUXELLES, CTR TUMEURS,INST JULES BORDET,MALAD INFECT CLIN, INVEST LAB, B-1000 BRUSSELS, BELGIUM
[3] UNIV LIBRE BRUXELLES, CTR TUMEURS, INST JULES BORDET, MICROBIOL LAB, B-1000 BRUSSELS, BELGIUM
[4] UNIV LIBRE BRUXELLES, CTR TUMEURS, INST JULES BORDET, ONCOL & CHIRURG EXPTL LAB, B-1000 BRUSSELS, BELGIUM
关键词
TNF-ALPHA; IL-6; ISOLATION PERFUSION; MELANOMA;
D O I
10.1016/1043-4666(92)90024-L
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In a phase II study, 18 patients with locally spreading melanoma or sarcoma of lower limb were treated by isolation perfusion (ILP) with hyperthermia and local infusion of high dose of recombinant human tumor necrosis factor α (rHuTNF-α) (4 mg). Bioactive TNF-α and interleukin 6 (IL-6) serum levels were measured serially, In the limb, TNF-α rapidly reached a plateau at 2 μ/ml, while IL-6 appeared later and progressively increased until the end of ILP. In the systemic circulation TNF-α rose up to a median concentration of 31 ng/ml after 1 hour, then decreased and became negligible after 6 hours. IL-6 peaked only after 5 hours after start of ILP (median: 36.7 ng/ml). In patients with substantial leakage towards systemic circulation, both cytokines peaked higher and earlier as compared with patients with minimal leakage. No correlation was found between cytokine levels and severity of side effects which in all cases were reversible. We conclude that high dose TNF-α infusion in ILP results in extremely high levels of bioactive TNF-α in the systemic circulation without irreversible side effect, and provokes a delayed blood release of large amounts of IL-6; there was a correlation between leakage from the limb during procedure and the magnitude of systemic cytokines levels. © 1992.
引用
收藏
页码:585 / 591
页数:7
相关论文
共 39 条
[1]  
ABBRUZZESE JL, 1989, CANCER RES, V49, P4057
[2]   RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA ADMINISTERED SUBCUTANEOUSLY OR INTRAMUSCULARLY FOR TREATMENT OF ADVANCED MALIGNANT DISEASE - A PHASE-I TRIAL [J].
AULITZKY, WE ;
TILG, H ;
GASTL, G ;
MULL, R ;
FLENER, R ;
VOGEL, W ;
HEROLD, M ;
BERGER, M ;
JUDMAIER, G ;
HUBER, C .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (04) :462-467
[3]   DIVERGENT EFFICACY OF ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA IN INTRAVASCULAR AND PERITONITIS MODELS OF SEPSIS [J].
BAGBY, GJ ;
PLESSALA, KJ ;
WILSON, LA ;
THOMPSON, JJ ;
NELSON, S .
JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (01) :83-88
[4]   CIRCULATING INTERLEUKIN-6 DURING A CONTINUOUS INFUSION OF TUMOR NECROSIS FACTOR AND INTERFERON-GAMMA [J].
BROUCKAERT, P ;
SPRIGGS, DR ;
DEMETRI, G ;
KUFE, DW ;
FIERS, W .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (06) :2257-2262
[5]   HIGH CIRCULATING LEVELS OF INTERLEUKIN-6 IN PATIENTS WITH SEPTIC SHOCK - EVOLUTION DURING SEPSIS, PROGNOSTIC VALUE, AND INTERPLAY WITH OTHER CYTOKINES [J].
CALANDRA, T ;
GERAIN, J ;
HEUMANN, D ;
BAUMGARTNER, JD ;
GLAUSER, MP .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (01) :23-29
[6]   PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK [J].
CALANDRA, T ;
BAUMGARTNER, JD ;
GRAU, GE ;
WU, MM ;
LAMBERT, PH ;
SCHELLEKENS, J ;
VERHOEF, J ;
GLAUSER, MP .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :982-987
[7]   ENDOTOXIN-INDUCED SERUM FACTOR THAT CAUSES NECROSIS OF TUMORS [J].
CARSWELL, EA ;
OLD, LJ ;
KASSEL, RL ;
GREEN, S ;
FIORE, N ;
WILLIAMSON, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1975, 72 (09) :3666-3670
[8]   INCREASED PERIPHERAL-BLOOD LEUKOCYTE CYTO-TOXIC ACTIVITY IN CANCER-PATIENTS DURING THE CONTINUOUS INTRAVENOUS ADMINISTRATION OF RECOMBINANT HUMAN-TUMOR NECROSIS FACTOR [J].
CHARNETSKY, PS ;
GREISMAN, RA ;
SALMON, SE ;
HERSH, EM ;
SCUDERI, P .
JOURNAL OF CLINICAL IMMUNOLOGY, 1989, 9 (01) :34-38
[9]  
CREAGAN ET, 1988, CANCER, V62, P2467, DOI 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO
[10]  
2-5